PB1864: BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR'S CHOICE OF IDELALISIB+RITUXIMAB OR BENDAMUSTINE+RITUXIMAB IN BTKI PRETREATED CLL/SLL (TRIAL IN PROGRESS). (23rd June 2022) - Sharman, J. P.; Jurczak, W.; Coombs, C. C.; Hill, M.; Wang, D.; Ku, N. C.; Guntur, A.; Shahda, S.; Leow, C. C.; Ghia, P.; Mato, A. R.